Search Results

You are looking at 1 - 10 of 122 items for :

  • "chemotherapeutic agents" x
Clear All
Full access

Anne A. Eaton, Camelia S. Sima and Katherine S. Panageas

Cherkin DC Ciol MA . Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases . J Clin Epidemiol 1992 ; 45 : 613 – 619 . 31. Lund JL Stürmer T Harlan LC . Identifying specific chemotherapeutic agents in Medicare

Full access

Sally Yowell Barbour

antagonist. They are recommended agents in both the acute and delayed settings. 8 – 10 Table 2 Emetogenicity of Intravenous Chemotherapeutic Agents Mechanism of Action The mechanism of action of corticosteroids in CINV remains relatively

Full access

Bhumsuk Keam, Jeong-Hoon Lee, Seock-Ah Im and Jung-Hwan Yoon

malignancy and the chemotherapeutic agents used. The 2 most common clinical settings in which HBV reactivation has been reported are during chemotherapy for lymphoma and during immunosuppressive treatment after hematopoietic stem cell transplantation (HSCT

Full access

David Y. Oh, Alan P. Venook and Lawrence Fong

(CRC). Chemotherapeutic agents such as oxaliplatin trigger immunogenic cell death, which leads to activation and maturation of dendritic cells (DCs) through release of small molecules, such as HMGB1 and ATP (through autophagy and endoplasmic reticulum

Full access

Margaret R. O'Donnell, Camille N. Abboud, Jessica Altman, Frederick R. Appelbaum, Steven E. Coutre, Lloyd E. Damon, James M. Foran, Salil Goorha, Lori J. Maness, Guido Marcucci, Peter Maslak, Michael M. Millenson, Joseph O. Moore, Farhad Ravandi, Paul J. Shami, B. Douglas Smith, Richard M. Stone, Stephen A. Strickland, Martin S. Tallman and Eunice S. Wang

Overview In 2010, approximately 12,330 people were diagnosed with and 8950 died of acute myeloid leukemia (AML).1 As the population ages, the incidence of AML, along with myelodysplasia, seems to be rising. Equally disturbing is the increasing incidence of treatment-related myelodysplasia and leukemia in survivors of childhood tumors and young adulthood, such as Hodgkin disease, sarcomas, breast and testicular cancers, and lymphomas. Ionizing radiation and occupational exposure to benzene and petrochemicals are also associated with AML.2 The NCCN AML Panel convenes annually to update guidelines for the diagnosis and treatment of AML in adults. Clinical trials have led to significant improvements in treatment in some areas, primarily in acute promyelocytic leukemia (APL). However, recent large clinical trials have highlighted the need for new, innovative strategies because outcomes for patients, particularly older patients, have not substantially changed in the past 3 decades. The panel has focused on outlining reasonable treatment options based on recent clinical trials and data from basic science, which may identify new risk factors and treatment approaches. In some areas, panel members have divergent opinions about the relative risks and benefits of various treatment options. Therefore, these guidelines attempt to provide a rationale for the inclusion of several treatment options in some categories. Initial Evaluation Initial evaluation has 2 objectives. The first is to characterize the disease process, including factors such as 1) prior toxic exposure, 2) myelodysplasia, and 3) karyotypic or molecular abnormalities, which may provide prognostic information that could influence responsiveness to chemotherapy and risk of...
Full access

Matthew G. Fury and David G. Pfister

20 weeks, respectively, for methotrexate. 14 An important general concept regarding clinical studies in R/M HNSCC is that no single chemotherapeutic agent has conclusively shown superiority in terms of overall survival over another drug in a

Full access

Matthieu Picard, Ursula A. Matulonis and Mariana Castells

. 44. Windom HH McGuire WP 3rd Hamilton RG Adkinson NF Jr . Anaphylaxis to carboplatin—a new platinum chemotherapeutic agent . J Allergy Clin Immunol 1992 ; 90 : 681 – 683 . 45. Goldberg A Confino-Cohen R Fishman A . A modified

Full access

Nikhil Khandelwal, Ian Duncan, Tamim Ahmed, Elan Rubinstein and Cheryl Pegus

order, and only 7% through a physician’s office. 12 Because oral chemotherapeutic agents are often covered under the pharmacy benefit plans for individuals who have insurance coverage, they are commonly dispensed through pharmacy channels. Their

Full access

Aki Morikawa and Andrew D. Seidman

within clinical trials have suggested that certain chemotherapeutic agents have differential antitumor activity in TNBC compared with non-TNBC. Thus, certain classes of chemotherapeutic agents have been preferentially evaluated in patients with TNBC

Full access

Ryan D. Gentzler and Jyoti D. Patel

regarding the optimal chemotherapeutic agents and duration of treatment. Unfortunately, despite investment of considerable patient and research resources, fewer than 5% of patients who present with metastatic disease are alive 5 years after diagnosis. 1 It